Machelle Sanders - Nov 13, 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Nov 13, 2025
Transactions value $
-$68,544
Form type
4
Date filed
11/17/2025, 04:07 PM
Previous filing
Jun 16, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SANDERS MACHELLE Director 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 2025-11-17 0001718020

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Sale -$68.5K -9.6K -23.86% $7.14 30.6K Nov 13, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were sold pursuant to a plan adopted by the Reporting Person on August 14, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale occurred automatically and does not represent a discretionary transaction by the Reporting Person.